Endo International has decided to delay a lawsuit against the FDA targeting the agency’s handling of compounding manufacturers.
The company brought the suit against the FDA after a site that produces bulk compounded medications began selling a drug Endo called “a copy” of its medication, Vasostrict. The practice of making bulk compounded medications has skyrocketed in recent years, but Endo accused the FDA of not properly evaluating this kind of manufacturing.
Last month, however, the FDA began making moves to restrict certain chemicals used in compounding medications, including an active ingredient used in Vasostrict.
Endo said it will now give the FDA until the end of the year create new regulations for compounding sites before pushing ahead with its litigation.